Uncategorized

Abbott Completes KOS Acquisition, Amylin Implications

With Abbott (NYSE:ABT) set to close their acquisition of Kos Pharmaceuticals (NASDAQ:KOSP) in the next few days attention is turning towards Pfizer (NYSE:PFE) and what they might do next. It had been speculated that Pfizer might try and trump Abbott’s bid for Kos. Since Pfizer announced they had stopped development of a key cholesterol drug the Street has been filled with rumors on which company they would acquire to bolster...

Have the inmates taken over the asylum

This morning a U S District Court judge ruled in favor for Pfizer (NYSE:PFE) and against Novo Nordisk (NYSE:NVO) when he denied a request to immediately halt distribution of Exubera. Even with this ruling Novo intends to pursue their patent infringement lawsuit against Pfizer. This is one case where Diabetic Investor is at a loss to explain Novo’s actions. Exubera is failing badly, as Diabetic Investor predicted it would, and...

Abbott Completes KOS Acquisition, Amylin Implications

With Abbott (NYSE:ABT) set to close their acquisition of Kos Pharmaceuticals (NASDAQ:KOSP) in the next few days attention is turning towards Pfizer (NYSE:PFE) and what they might do next. It had been speculated that Pfizer might try and trump Abbott’s bid for Kos. Since Pfizer announced they had stopped development of a key cholesterol drug the Street has been filled with rumors on which company they would acquire to bolster...

Abbott Diabetes Care Management Shake Up

Diabetic Investor has learned that Abbott (NYSE:ABT) Diabetes Care is in the midst of a management shake up. Beginning in 2007 this new management team will face a host of issues. Not the least of which is what they plan to do with the Navigator, the company’s continuous glucose monitoring system which is still awaiting Food and Drug Administration (FDA) approval. Originally submitted to the FDA back in December of...

Acomplia Update

This morning Sanofi-Aventis (NYSE:SNY) announced that the Food and Drug Administration (FDA) has considered its October 26th, 2006 resubmission to be a complete, class 2 response to the FDA February 17th, 2006 action letter. A final decision on Acomplia® is expected in late April 2007. This news comes on the heels of the company’s release of data from their SERENADE study at the International Diabetes Federation (IDF) World Diabetes...

Lilly Update

Today Lilly (NYSE:LLY) provided the investment community with an update and the news for their diabetes franchise was mixed. While the company acknowledge problems with their insulin business Diabetic Investor isn’t sure their plans for the future will do much to help them regain market share. To illustrate just how far Lilly has fallen in the insulin market the company showed a slide today that indicated they were gaining...

Continuous monitoring mixed results

Last week on the Monday after the Thanksgiving holiday Medtronic (NYSE:MDT) released a press release with the title “GuardControl Study shows improved glycemic control in type 1 diabetes using real-time continuous monitoring.” After reading through the press release and then reading the study which was published in the December 2006 Issue of Diabetes Care, Medtronic may wish to re-think their PR strategy. The study consisted of 81 children and...

Big Day for Big Pharma

While the markets are digesting the news of Pfizer’s (NYSE:PFE) announcement to halt further development of Torcetrapib and sorts out just what the company will do next. Another large pharmaceutical company GlaxoSmithKline (NYSE:GSK) was making their case for the Avandia franchise. These two events although involving different disease states do have an impact on the diabetes sector, if albeit for different reasons. First let’s take a look at what...

Amylin – Concerns over Byetta Prescription Growth

This afternoon Amylin (NASDAQ:AMLN) presented at the Piper Jaffray Healthcare Conference and based on the presentation it’s clear the Street is concerned over the future of Byetta. While the product has performed very well the bulk of concern centers around whether or not prescriptions for Byetta have begun to level off and just what affect Januvia is having on prescription growth. As Diabetic Investor indicated earlier this week shares of...

The IDF World Conference – What to expect.

Next week the International Diabetes Federation (IDF) will be hosting the 19th World Diabetes Conference in Cape Town, South Africa. Investors should mark their calendars for two very important presentations. The first will held on Monday December 4th at 11 a.m. EST by GlaxoSmithKline (NYSE:GSK) which will review their Avandia franchise. On Tuesday December 5th at 9:30 a.m. EST Sanofi-Aventis (NYSE:SNY) will release data from the Acomplia® Serenade study. ...